Aromatase Inhibitor-Associated Musculoskeletal Symptoms #402

“Cancer of the Breast (Female)—Cancer Stat Facts.” SEER, seer.cancer.gov/statfacts/html/breast.html (Last accessed September 11, 2020).

American Cancer Society. Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society, Inc. 2019. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf

Goss PE , Ingle JN , Martino S , et al.: Randomized trial of letrozole following tamoxifen as extended therapy in receptor-positive breast cancer. Updated findings from NCIC CTG MA.17. J Natl Cancer Inst, 2005; 97:1262–1271.

Lombard JM , Zdenkowski N , Wells K , et al.: Aromatase inhibitor induced musculoskeletal syndrome: A significant problem with limited treatment options. Support Care Cancer, 2016; 24:2139–2146.

Presant CA , Bosserman L , Young T , et al.: Aromatase inhibitor-associated arthralgia and/or bone pain: Frequency and characterization in non-clinical trial patients. Clin Breast Cancer, 2007; 7:775–778.

Crew KD , Greenlee H , Capodice J , et al.: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol, 2007; 25:3877–3883.

Cella D , Fallowfield L , Barker P , et al.: Quality of life of postmenopausal women in the ATAC (“Arimidex,” Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat, 2006; 100:273–284.

Zhang Y , McAlindon TE , Hannan MT , et al.: Estrogen replacement therapy and worsening of radiographic knee OA: The Framingham Study. Arthritis Rheum, 1998; 41:1867–1873.

Gallicchio L , MacDonald R , Helzlsouer KJ : Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer. J Cancer Res Clin Oncol, 2013; 139:837–843.

Mao JJ , Stricker C , Bruner D , et al.: Patterns and risk factors associated with aromatase inhibitor related arthralgia among breast cancer survivors. Cancer, 2009; 115:3631–3639.

Lintermans A , Laenen A , Van Calster B , et al.: Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol, 2013; 24:350–355.

Wisotzky EM, Power K: Aromatase Inhibitor-Induced Musculoskeletal Symptoms. In: Cancer Rehabilitation, 2nd ed. demosMedical, an imprint of Springer Publishing Company, 2019, pp. 972–978.

Mardani-Kivi M , Mobarakeh MK , Bahrami F , et al.: Corticosteroid injection with or without thumb spica cast for de Quervain tenosynovitis. J Hand Surg Am, 2014; 39:37–41.

Henry NL , Unger JM , Schott AF , et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol, 2018; 36:326–332.

Irwin ML , Cartmel B , Gross CP , et al.: Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol, 2015; 33:1104–1111.

Kubo M , Onishi H , Kuroki S , et al.: Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res, 2012; 32:2331–2336.

Dawn L. Hershman, Unger JM, Greenlee H, et al.: Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer. JAMA 2018;320:167.